Tradestie Institutional Equity Comparison Engine

LXEO vs OKUR โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LXEO Overall Edge

LXEO Captures Institutional Edge (2โ€“2 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lexeo Therapeutics, Inc. Common Stock (LXEO) driven by superior Valuation, Options & Structure while OKUR counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, LXEO trades at 5.3x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus OKUR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, LXEO sits in BREAKDOWN (85th %ile IV; Dealer Gamma Walls on Pro) against OKUR sits in SURGE (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LXEO
LXEO 5.3x vs OKUR N/M Fwd P/E
Growth & Margin Winner OKUR
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner OKUR
1Y -67.4% vs -2.2% ยท 52W Pos 5% vs 20%
Options & Structure Winner LXEO
BREAKDOWN (85th %ile IV) vs SURGE (100th %ile IV)
LXEO NASDAQ
Lexeo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.96
+0.34% 1D
Market Cap $244.2M
1M Return +2.42%
1Y Return -67.44%
Forward P/E 5.3x
Unified AI Score
45.5 / 100 HOLD
Tech 46.0 Fund 57.0 Flow 65.0 Mom 70.0
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
1M Return +4.65%
1Y Return -2.17%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LXEO -67.44% OKUR -2.17% Spread: +65.27 pp (OKUR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
LXEO TTM Op. Margin: 0.0% OKUR TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LXEO vs OKUR. Trailing 12-month operating profitability (LXEO 0.0% vs OKUR 0.0%) and valuation multiples (LXEO 5.3x vs OKUR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LXEO (5) vs OKUR (2)
Institutional Metric LXEO OKUR Criterion Row Winner
Market Capitalization Scale $244.2M $113.7M Larger Scale LXEO
Trailing P/E Ratio Valuation 5.3x N/M Lower Multiple LXEO
Forward P/E Ratio Valuation 5.3x N/M Lower Multiple LXEO
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.4% -55.2% Higher ROE OKUR
52-Week Range Position Momentum 5% ($3โ€“$11) 20% ($2โ€“$5) Stronger Trend OKUR
Beta / 30D Volatility Risk Regime 1.67ฮฒ ยท 91% Vol 0.96ฮฒ ยท 100% Vol Lower Realized Risk LXEO
Unified Institutional Score Composite Signal 45.5 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite LXEO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LXEO vs OKUR Buy Guide
LXEO BREAKDOWN
151d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live LXEO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
OKUR SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live OKUR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LXEO nor OKUR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.